Sign In
Buy CRMD
$8.23
+0.0600 (+0.734%)
At Close: Jun 03, 2026
CorMedix Inc. Announces New Commercial Agreement
10:52am, Monday, 09'th Sep 2024
BERKELEY HEIGHTS, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and condit
CorMedix (CRMD) Is Up 10.44% in One Week: What You Should Know
01:01pm, Thursday, 05'th Sep 2024
Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think CorMedix (CRMD) Could Surge 117.77%: Read This Before Placing a Bet
10:57am, Thursday, 05'th Sep 2024
The consensus price target hints at an 117.8% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 142.25%: Here's is How to Trade
10:55am, Tuesday, 20'th Aug 2024
The mean of analysts' price targets for CorMedix (CRMD) points to a 142.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analys
CorMedix Inc. (CRMD) Q2 2024 Earnings Call Transcript
02:08pm, Wednesday, 14'th Aug 2024
CorMedix Inc. (NASDAQ:CRMD ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Joe Todisco - CEO Matt David - EVP and CFO Liz Hurlburt - EVP
CorMedix (CRMD) Reports Q2 Loss, Tops Revenue Estimates
09:45am, Wednesday, 14'th Aug 2024
CorMedix (CRMD) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.25 per share a year ago.
CorMedix Inc. Reports Second Quarter and Six Month 2024 Financial Results and Provides Business Update
07:30am, Wednesday, 14'th Aug 2024
BERKELEY HEIGHTS, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 14, 2024
08:30am, Wednesday, 07'th Aug 2024
BERKELEY HEIGHTS, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. Announces Outpatient Availability of DefenCath
08:00am, Wednesday, 03'rd Jul 2024
BERKELEY HEIGHTS, N.J., July 03, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditi
CorMedix Inc. Announces CMS Grants Pass-Through Status to Defencath
08:30am, Thursday, 06'th Jun 2024
BERKELEY HEIGHTS, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
08:30am, Tuesday, 28'th May 2024
BERKELEY HEIGHTS, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditio
CorMedix Inc. (CRMD) Q1 2024 Earnings Call Transcript
05:48pm, Saturday, 11'th May 2024
CorMedix Inc. (NASDAQ:CRMD ) Q1 2024 Results Conference Call May 9, 2024 8:30 AM ET Company Participants Dan Ferry - LifeSci Advisors Joe Todisco - Chief Executive Officer Matt David - EVPr and CFO Be
CorMedix Inc. to Participate in Two Upcoming Investor Conferences
08:30am, Friday, 10'th May 2024
BERKELEY HEIGHTS, N.J., May 10, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening d
CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
07:30am, Thursday, 09'th May 2024
BERKELEY HEIGHTS, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening d
CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024
08:30am, Monday, 06'th May 2024
BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening d
